ArvinasARVN
ARVN
About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Employees: 430
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
315% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $7.41M
57% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 51
40% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]
7.91% more ownership
Funds ownership: 103.54% [Q3] → 111.44% (+7.91%) [Q4]
4% less funds holding
Funds holding: 205 [Q3] → 196 (-9) [Q4]
16% less capital invested
Capital invested by funds: $1.75B [Q3] → $1.47B (-$280M) [Q4]
18% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 34
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
40%
upside
Avg. target
$30
250%
upside
High target
$81
842%
upside
13 analyst ratings
9 positive
69%
4 neutral
31%
0 negative
0%
Goldman Sachs Paul Choi 53% 1-year accuracy 8 / 15 met price target | 40%upside $12 | Neutral Maintained | 17 Apr 2025 |
Truist Securities Joon Lee 41% 1-year accuracy 17 / 41 met price target | 144%upside $21 | Buy Maintained | 9 Apr 2025 |
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target | 842%upside $81 | Buy Reiterated | 7 Apr 2025 |
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target | 40%upside $12 | Equal-Weight Maintained | 13 Mar 2025 |
Guggenheim Michael Schmidt 27% 1-year accuracy 10 / 37 met price target | 272%upside $32 | Buy Maintained | 13 Mar 2025 |
Financial journalist opinion
Based on 5 articles about ARVN published over the past 30 days
Negative
Zacks Investment Research
1 week ago
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Benzinga
2 weeks ago
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.
Neutral
GlobeNewsWire
2 weeks ago
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers –
Neutral
GlobeNewsWire
3 weeks ago
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader – – Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –
Positive
Benzinga
3 weeks ago
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
Zacks Investment Research
1 month ago
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 month ago
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Arvinas (ARVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
1 month ago
Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Negative
Zacks Investment Research
1 month ago
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Negative
Benzinga
1 month ago
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas, Inc. ARVN and Pfizer Inc. PFE released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.
Charts implemented using Lightweight Charts™